Novel securinine derivatives as topoisomerase I based antitumor agents
- Eur J Med Chem. 2016 Oct 21:122:149-163. doi: 10.1016/j.ejmech.2016.06.021.
- 1. College of Pharmacy, Jinan University, Guangzhou 510632, PR China.
- 2. College of Pharmacy, Jinan University, Guangzhou 510632, PR China. Electronic address: [email protected].
- 3. College of Pharmacy, Jinan University, Guangzhou 510632, PR China. Electronic address: [email protected].
DNA Topoisomerase I (Topo I) has been validated as a target for Anticancer agents. In this study, a series of novel securinine derivatives bearing β'-hydroxy-α,β-unsaturated ketone moiety were designed and synthesized via a Baylis-Hillman reaction for screening as Topo I inhibitors and antitumor agents. Their Topoisomerase I inhibitory activity as well as their cytotoxicity against four human Cancer cell lines (A549, HeLa, HepG2, SH-SY5Y) were evaluated, and two pairs of diastereomers 4a-1 and 4a-6 with significant Topo I inhibitory activity and potent anti-proliferative activity against Cancer cell lines were identified. The diastereomers were separated, and absolute configurations of five pairs of diastereomers were identified based on X-ray crystallographic analysis and circular dichroism (CD) spectra analysis. Further mechanism studies of the most active compounds 4a-1-R and 4a-1-S indicated that this kind of securinine derivative exhibits a different inhibitory mechanism from that of camptothecin, an established Topo I Inhibitor. Unlike camptothecin, compounds 4a-1-R and 4a-1-S specifically inhibits the combination of Topo I and DNA rather than forming the drug-enzyme-DNA covalent ternary complex. In addition, molecular docking and molecular dynamic studies revealed the binding patterns of these compounds with Topo I.